BORN Expands With Alkeon B2B Market Network Platform Transforming Commercial Models, Starting With the Trade Show Industry
2.3.2021 17:12:00 EET | Business Wire | Press release
BORN, announces the expansion of innovative B2B subsidiary Alkeon, the world's first global SaaS market-network combining content, community, and commerce to connect buyers and sellers through a best-in-class platform, powered by machine learning. The 2020 pandemic generated a tremendous and immediate need for companies of all categories to pivot at a moment’s notice, with over 10,000 global trade shows completely upended due to cancellations of physical events. BORN, a purpose driven lifestyle company dedicated to reimagining the discovery, transaction and connection of the B2B and B2C communities, found an opportune moment to quickly scale and enhance their technology solutions. The company formally established Alkeon, an enterprise dedicated to supporting the needs of companies who are adapting to the current and future landscapes and need the right partner to support them through the process.
Combining aesthetic and function to create designed technology, Alkeon is a market-network company that enables brands to create an always-on commercial model, digitally optimize their existing infrastructure, capture detailed audience insights and more. Starting with the immediate needs of the global trade show market, Alkeon represents over 15,000 buyers and 150,000 new products by the end of the year. The B2B solution has seen hyper growth and solidified contracts from some of the most influential global trade shows including Tranoï (part of GL Events), Cosmoprof, Brand Assembly, Reassemble, Esxence and Bridal Harrogate.
Founder and CEO of BORN, Jean-Christophe states, “We have seen gaps in the B2B and B2C supply chains for several years, with many aspects of both still operating with analogue systems that lack the benefits of full digital capabilities, audience intelligence and ways to expand and enhance traditional commercial models. The last year has made these gaps stark, leaving many companies in a position to innovate quickly in order to survive. The trade show audience was not only deeply disrupted, but is crucial for global commerce. The tech solutions that we’ve developed have implications for several industries, but we chose to focus on this important category that supports economies around the world. Longterm, businesses, including trade shows, will need a hybrid model that combines the best of technology with the great benefits of physical interaction. We’re creating the solutions for now and well into the future.”
Alkeon’s technology platform empowers trade shows to digitally transform their business, and expand their business internationally with buyers, agents, showrooms and distributors. Brands using BORN's Alkeon service can select a package that ranges from $99 a month to $15,000 a year with various offerings, including intelligent matchmaking, a suite of connection tools such as in-app messaging and video meetings, actionable insights about their business such as buyer engagement and trending product reports. Alkeon offers buyers best-in-class product discovery experience powered by machine learning, delivering personalized product recommendations, curated product lists, and the ability to save products.
“Early on, we asked ourselves the question, “Why can’t B2B be beautiful?”. So we set out with the goal to delight wholesale buyers with a refined, feature-rich product discovery and purchase experience typically reserved for direct-consumer experiences.” - Brendan Wypich, Chief Design & Product Officer.
The platform provides a sleek interface for each brand to present their story and products so that buyers can make quick and informed business decisions. Alkeon streamlines a brand’s workflows by providing full transparency and clear tracking of buyer order flows from initial interest through to purchase order all while staying in constant contact with the buyer. The result is a simplified wholesale buying process that future-proofs the brand’s operations while scaling their business footprint.
BORN began developing the Alkeon technology well before the pandemic hit. Alkeon offers a pleasing and educational discovery experience along with a seamless infrastructure. With quick expansion, BORN and Alkeon will chart the course for the future of retail and wholesale, using the best of the latest technology to learn and adapt, curate and personalize and allow for broader market access. The benefits of the technology have game-changing implications for tradeshows, showrooms, brands, media companies, press agents and buyers.
About BORN:
BORN specializes in digital, data-led solutions to digitize retail supply chains and reimagine discovery and transaction online. BORN owns Alkeon, a suite of B2B solutions and software products that digitize tradeshows and showrooms, as well as Born.com, a platform connecting thousands of luxury design-led brands with premium retailers. BORN is led by CEO Jean-Christophe Chopin, ex-founder of E*Trade EU and Verisign EU.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005254/en/
Contact information
Press: Stephanie Gotch SG@PartnersAndAssoicatesAgency.com 917-583-8606
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
